No.12-78

November 29, 2012
Eisai Co., Ltd.

# EISAI TO PRESENT NEW RESEARCH ON HALAVEN® AT 35TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that new clinical study results on the company’s novel anticancer agent Halaven® (generic name: eriyener RI4 na(TEi Co., L2EH.1r symposium will be held December 4-8, 2012, in San Antonio, Texas in the United States.

The studies highlight Eisai’s current and ongoing research efforts to establish the clinical benefits of Halaven and maximize the drug’s value. This year’s SABCS will also include an oral presentation on December 7 highlighting the results of a head-to-head study of Halaven versus capecitabine (Study 301) that was conducted in 1,102 patients with locally advanced or metastatic breast cancer. Date: December 5 (Wed), 17:00-19:00

| | |
|---|---|
| | ***Poster Session*** \| December 7 (Fri), 17:00-19:00 |

(Continued of following page)

| | |
|---|---|
| Halaven®<br>(eribulin mesylate)<br>Abstract no:<br>**P1-13-11** | Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a Phase II, single-arm feasibility study<br>***Poster Session*** \| December 5 (Wed), 17:00-19:00 |
| Halaven®<br>(eribulin mesylate)<br>Abstract no:<br>**P6-11-14** | Post-hoc safety and tolerability assessment in patients receiving palliative radiation during treatment with eribulin mesylate for metastatic breast cancer<br>***Poster Session*** \| December 8 (Sat), 7:00-8:30 |
| N/A<br>Abstract no:<br>**P6-09-06** | Family members' burden in patients with metastatic and early stage breast cancer<br>***Poster Session*** \| December 8 (Sat), 7:00-8:30 |

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120